Dr. Thakur Raghu Raj Singh is Reader in Pharmaceutics in the School of Pharmacy, Queen's University Belfast. He has obtained his Ph.D. in Drug Delivery from School of Pharmacy, Queens University Belfast (2009), M.Sc in Pharmaceutical Sciences from University Science Malaysia (2006) and B.Pharm from Jawaharlal Nehru Technological University, India (2002).

Dr. Thakur’s research interests are in the design and physicochemical characterisation of advanced polymeric drug delivery systems for ocular, transdermal and topical applications. In particular, his current research involves the fabrication and design of novel long-acting injectable and implantable drug delivery systems for treating back of the eye disorders. His research on the treatment of eye disorders has led to the formation of Re-Vana Therapeutics Ltd., where he is currently serving as a Chief Technical Officer (CTO). Re-Vana Therapeutics is an ocular pharmaceutical & drug delivery company focused on addressing ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and other ocular infections.  

He is the Chair for Ocular Delivery (OcD) Focus Group supported by the mission of Controlled Release Society (CRS) that engages researchers, industry representatives, and regulatory experts in the advancement of technologies designed to protect or restore vision

He has authored over 150 scientific publications, including 54 peer-reviewed research papers, 10 book chapters and 4 textbooks. He has been an invited speaker at a number of national/international meetings. He is currently Editorial Board member of the International Journal of Pharmacy & Pharmacology, Chronicles of Pharmacy and SCIENCEDOMAIN international, and Scientific advisor for Journal of Pharmaceutical Sciences. He is a reviewer for several high impact journals.